Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients

Transplantation

Volumn 83, Issue 8, 2007, Pages 1027-1034

  Burroughs, Thomas E ^a,d   Swindle, Jason ^a   Takemoto, Steven ^a   Lentine, Krista L ^a   Machnicki, Gerardo ^a   Irish, William D ^b   Brennan, Daniel C ^c   Schnitzler, Mark A ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Center for Outcomes Research   (United States)

Author keywords

Complications; Immunosuppression; Post transplantation diabetes

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

AFRICAN AMERICAN; AGING; ARTICLE; BODY MASS; COLD ISCHEMIA; DIABETES MELLITUS; DISEASE ASSOCIATION; EYE DISCHARGE; EYE DISEASE; GRAFT RECIPIENT; GRAFT REJECTION; HEPATITIS C; HUMAN; HYPEROSMOLALITY; HYPERTENSION; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KETOACIDOSIS; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MULTIVARIATE ANALYSIS; NEUROLOGIC DISEASE; OBESITY; ONSET AGE; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; SHOCK;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DIABETES COMPLICATIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; TACROLIMUS; TIME FACTORS;

EID: 34247463674     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000259617.21741.95     Document Type: Article

References (38)

1. Montori VM, Velosa JA, Basa A, et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25: 583.
2. Kasiske BL, Synder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
3. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590.
4. Jindal RM, Sidner RA, Milgrom ML. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 1997; 16: 242.
5. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004; 4: 583.
6. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005; 19: 291.
7. Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant associated diabetes? Transplantation 1998; 65: 380.
8. Skyler JS, Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev 2002; 18(Suppl 3): S21.
9. Leese B. The costs of diabetes and its complications. Soc Sci Med 1992; 35: 1303.
10. Nathan DM, Cleary PA, Backlund JY, et al. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643.
11. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes 1999; 48: 383.
12. The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116: 874.
13. Grinyo JM. Steroid sparing strategies in renal transplantation. Nephrol Dial Transplant 2005; 20: 2028.
14. Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68: 396.
15. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977.
16. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436.
17. Vincenti F, Laskow DA, Neylan JF, et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61: 1576.
18. Sperschneider H. A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. Transplant Proc 2001; 33: 1279.
19. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999; 318: 104.
20. Schnitzler MA, Hardinger KL, Brennan DC. Tacrolimus dose adjustment and post-transplant diabetes mellitus in US renal transplantation. Tacrolimus dose adjustment and post-transplant diabetes mellitus in US renal transplantation. Am J Transplant 2004; 4(Suppl 8): 345.
21. Hebert PL, Geiss LS, Tierney EF, et al. Identifying persons with diabetes using Medicare claims data. Am J Med Qual 1999; 14: 270.
22. Gurwitz JH, Bohn RL, Glynn RJ, et al. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med 1993; 118: 273.
23. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
24. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265.
25. Allison P. Survival Analysis Using SAS: A Practical Guide. Cary, NC: SAS Institute Inc., 1995.
26. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977.
27. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 837.
28. Davis TE, Turner RC, Stratton EM, et al. UK Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM. Diabetes Care 1997; 20: 1435.
29. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 136.
30. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kid Int 2003; 63: 225.
31. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703.
32. Matthews DR, Stratton IM, Aldington SJ, et al. Risks of progression of retinopathy and vision loss related to tight blood pressure control in Type 2 diabetes mellitus. Arch Ophthalmol 2004; 122: 1631.
33. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979.
34. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003; 75: SS3.
35. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65: 515.
36. Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with post-transplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002; 13: 1374.
37. O'Connor P, Rush W, Pronk N, Cherney L. Identifying diabetes mellitus or heart disease among health maintenance organization members: sensitivity, specificity, predictive value, and cost of survey and database methods. Am J Managed Care 1998; 4: 335.
38. Rector T, Wickstron S, Shah M, et al. Specificity and sensitivity of claims-based algorithms for identifying members of Medicare+ Choice health plans that have chronic medical conditions. Health Services Res 2004; 39: 1839.